Cancer Treatment-Related Cardiotoxicity Publications
This list provides links to scientific publications that may be of interest to researchers studying cardiotoxicities related to cancer treatments, but it is not exhaustive. If you have suggestions for additional publications to add, please contact Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N., Program Director in EGRP's Clinical and Translational Epidemiology Branch.
You may click on the table headers below to sort alphabetically by the first author, publication year, scientific area, cancer treatment, subject population, toxicity, or study type.
Filter Table
Pub. Year:
Scientific Area:
Cancer Treatment:
Subject Pop.:
Toxicity:
Study Type:
| Article | Pub. Year | Scientific Area | Cancer Treatment | Subject Pop. | Toxicity * | Study Type |
|---|---|---|---|---|---|---|
Fedele C, Riccio G, Coppola C, et al: Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors . Breast Cancer Res Treat. 133:511-21, 2012 |
2012 | Detection | Targeted Therapy | Pre-clinical | LVEF / Heart Failure | Biological Study |
| Lenihan D, Suter T, Brammer M, et al: Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 23:791-800, 2012 |
2012 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| McMurray JJ, Adamopoulos S, Anker SD, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 |
2012 | General | Multi-modality | Adult | LVEF / Heart Failure | Guidelines |
| Serrano C, Cortes J, De Mattos-Arruda L, et al: Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 23:897-902, 2012 |
2012 | Epidemiology / Risk | Targeted Therapy | Older Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Steingart RM, Bakris GL, Chen HX, et al: Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 163:156-63, 2012 |
2012 | General | Targeted Therapy | Adult | Hypertension | Consensus |
| Tarantini L, Cioffi G, Gori S, et al: Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 18:113-9, 2012 |
2012 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Tarantini L, Gori S, Faggiano P, et al: Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012 |
2012 | Epidemiology / Risk | Targeted Therapy | Older Adult | LVEF / Heart Failure & Hyptertension | Observational Epidemiological Study - Retrospective |
| Visscher H, Ross CJ, Rassekh SR, et al: Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 30:1422-8, 2012 |
2012 | Epidemiology / Risk | Chemotherapy | Pediatric | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Aapro M, Bernard-Marty C, Brain EG, et al: Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 22:257-67, 2011 |
2011 | General | Chemotherapy | Older Adult | LVEF / Heart Failure | Consensus |
| Appel JM, Sogaard P, Mortensen CE, et al: Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer. J Am Soc Echocardiogr. 24:200-6, 2011 |
2011 | Detection | Chemotherapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Cendales R, Schiappacasse L, Schnitman F, et al: Helical tomotherapy in patients with breast cancer and complex treatment volumes. Clin Transl Oncol. 13:268-74, 2011 |
2011 | Prevention | Radiation | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Eschenhagen T, Force T, Ewer MS, et al: Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 13:1-10, 2011 |
2011 | General | Multi-modality | Pre-clinical | General cardiotoxicity | Consensus |
| Feola M, Garrone O, Occelli M, et al: Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 148:194-8, 2011 |
2011 | Detection | Chemotherapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Haque R, Yood MU, Geiger AM, et al: Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 20:2120-6, 2011 |
2011 | Epidemiology / Risk | Radiation | Older Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Konishi M, Haraguchi G, Ohigashi H, et al: Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res. 89:309-19, 2011 |
2011 | Prevention | Chemotherapy | Pre-clinical | LVEF / Heart Failure | Biological Study |
| Morris PG, Chen C, Steingart R, et al: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 17:3490-9, 2011 |
2011 | Detection | Multi-modality | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Pituskin E, Haykowsky M, Mackey JR, et al: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 11:318, 2011 |
2011 | Prevention | Targeted Therapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Sawaki M, Mukai H, Tokudome N, et al: Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Breast Cancer. 2011 |
2011 | Epidemiology / Risk | Targeted Therapy | Older Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Sawaya H, Sebag IA, Plana JC, et al: Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 107:1375-80, 2011 |
2011 | Epidemiology / Risk | Chemotherapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Tikoo K, Sane MS, Gupta C: Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy. Toxicol Appl Pharmacol. 251:191-200, 2011 |
2011 | Prevention | Chemotherapy | Pre-clinical | LVEF / Heart Failure | Biological Study |
| van Hasselt JG, Boekhout AH, Beijnen JH, et al: Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin Pharmacol Ther. 90:126-32, 2011 |
2011 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Xin YF, Wan LL, Peng JL, et al: Alleviation of the acute doxorubicin-induced cardiotoxicity by Lycium barbarum polysaccharides through the suppression of oxidative stress. Food Chem Toxicol. 49:259-64, 2011 |
2011 | Prevention | Chemotherapy | Pre-clinical | LVEF / Heart Failure | Biological Study |
| Blaes AH, Gaillard P, Peterson BA, et al: Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat. 122:585-90, 2010 |
2010 | Prevention | Chemotherapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 55:213-20, 2010 |
2010 | Cardiotoxicity Management | Chemotherapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 28:3910-6, 2010 |
2010 | Detection | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Georgakopoulos P, Roussou P, Matsakas E, et al: Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 85:894-6, 2010 |
2010 | Prevention | Chemotherapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Lenihan DJ, Cardinale D, Cipolla CM: The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 53:88-93, 2010 |
2010 | General | Multi-modality | General | General cardiotoxicity | Consensus |
| Lindenfeld J, Kelly PA: Developing a cardiology-oncology clinical practice guideline. Prog Cardiovasc Dis. 53:173-9, 2010 |
2010 | General | Multi-modality | General | General cardiotoxicity | Consensus |
| Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 11:950-61, 2010 |
2010 | Epidemiology / Risk | Chemotherapy | Pediatric | LVEF / Heart Failure | Randomized Clinical Trial |
| Maitland ML, Bakris GL, Black HR, et al: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 102:596-604, 2010 |
2010 | General | Targeted Therapy | Adult | Hypertension | Consensus |
| Meacham LR, Chow EJ, Ness KK, et al: Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 19:170-81, 2010 |
2010 | Epidemiology / Risk | Multi-modality | Pediatric Cancer Survivors | General cardiotoxicity | Observational Epidemiological Study - Retrospective |
| van Dalen EC, Michiels EM, Caron HN, et al: Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev:CD005006, 2010 |
2010 | Epidemiology / Risk | Chemotherapy | Adult | LVEF / Heart Failure | Meta Analysis / Systematic Review |
| Van der Pal HJ, van Dalen EC, Hauptmann M, et al: Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 170:1247-55, 2010 |
2010 | Epidemiology / Risk | Multi-modality | Pediatric Cancer Survivors | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Yoon GJ, Telli ML, Kao DP, et al: Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 56:1644-50, 2010 |
2010 | Cardiotoxicity Management | Multi-modality | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Bi X, Deng Y, Zeng F, et al: Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients. J Huazhong Univ Sci Technolog Med Sci. 29:391-4, 2009 |
2009 | Detection | Chemotherapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Du XL, Xia R, Liu CC, et al: Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 115:5296-308, 2009 |
2009 | Epidemiology / Risk | Chemotherapy | Older Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Guglin M, Hartlage G, Reynolds C, et al: Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 15:651-7, 2009 |
2009 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Hare JL, Brown JK, Leano R, et al: Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J. 158:294-301, 2009 |
2009 | Detection | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Prospective |
| Hunt SA, Abraham WT, Chin MH, et al: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 119:e391-479, 2009 |
2009 | Cardiotoxicity Management | Multi-modality | General | LVEF / Heart Failure | Guidelines |
| Jones AL, Barlow M, Barrett-Lee PJ, et al: Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 100:684-92, 2009 |
2009 | Cardiotoxicity Management | Targeted Therapy | Adult | LVEF / Heart Failure | Consensus |
| Morris PG, Dickler M, McArthur HL, et al: Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 27:6117-23, 2009 |
2009 | Epidemiology / Risk | Chemotherapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 339:b4606, 2009 |
2009 | Epidemiology / Risk | Multi-modality | Pediatric Cancer Survivors | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Dranitsaris G, Rayson D, Vincent M, et al: The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 107:443-50, 2008 |
2008 | Epidemiology / Risk | Chemotherapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Mackey JR, Clemons M, Cote MA, et al: Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 15:24-35, 2008 |
2008 | Cardiotoxicity Management | Targeted Therapy | Adult | LVEF / Heart Failure | Consensus |
| Perez EA, Koehler M, Byrne J, et al: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 83:679-86, 2008 |
2008 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Ryberg M, Nielsen D, Cortese G, et al: New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 100:1058-67, 2008 |
2008 | Epidemiology / Risk | Chemotherapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Telli ML, Witteles RM, Fisher GA, et al: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 19:1613-8, 2008 |
2008 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 25:3991-4008, 2007 |
2007 | Epidemiology / Risk | Multi-modality | Adult | LVEF / Heart Failure | Meta Analysis / Systematic Review |
| Robert J: Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol. 7:135-9, 2007 |
2007 | Detection | Chemotherapy | Pre-clinical | LVEF / Heart Failure | Biological Study |
| Suter TM, Procter, M, van Veldhuisen, DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J of Cl Oncol. 25:3859-65, 2007 |
2007 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 114:2474-81, 2006 |
2006 | Prevention | Chemotherapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Guarneri V, Lenihan DJ, Valero V, et al: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 24:4107-15, 2006 |
2006 | Epidemiology / Risk | Targeted Therapy | Adult | LVEF / Heart Failure | Observational Epidemiological Study - Retrospective |
| Focan C, Graas MP, Beauduin M, et al: Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. Anticancer Res. 25:1211-7, 2005 |
2005 | Prevention | Chemotherapy | Adult | LVEF / Heart Failure | Randomized Clinical Trial |
| Swain SM, Vici P: The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol. 130:1-7, 2004 |
2004 | Prevention | Chemotherapy | General | LVEF / Heart Failure | Consensus |
| Schultz PN, Beck ML, Stava C, et al: Health profiles in 5836 long-term cancer survivors. Int J Cancer. 104:488-95, 2003 |
2003 | Epidemiology / Risk | Multi-modality | Adult | General cardiotoxicity | Observational Epidemiological Study - Prospective |
| Kremer LCM, van der Pal HJH, Offringa M, et al: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology. 13:819-829, 2002 |
2002 | Epidemiology / Risk | Chemotherapy | Adult | LVEF / Heart Failure | Meta Analysis / Systematic Review |
| Mertens AC, Yasui Y, Neglia JP, et al: Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 19:3163-72, 2001 |
2001 | Epidemiology / Risk | Multi-modality | Pediatric Cancer Survivors | General cardiotoxicity | Observational Epidemiological Study - Retrospective |
*LVEF = left ventricular ejection fraction